Editorial review · United States
CJC-1295
Source review:
Approval and product status
Still being studied. This review found no FDA-approved CJC-1295 product in the United States.
Some products use the name CJC-1295 for different chemical forms, including different salts. Some have a chemical part called DAC, and some do not. FDA says evidence for the DAC form cannot prove the same effects for a no-DAC form. These products are not automatically the same as modified GRF 1-29 or pharmacy-made mixtures with other ingredients.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Limited
- Studies in people measured hormone levels. They did not test lasting health benefits.
- Body effects · Moderate
- Short studies in healthy adults found that CJC-1295 raised growth hormone and insulin-like growth factor 1 (IGF-1) for a time.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
FDA says compounded CJC-1295 may pose a risk of unwanted immune reactions when given by certain routes. FDA also describes possible quality concerns, including peptide impurities and incomplete information about the active ingredient. FDA reports serious events associated with CJC-1295, including a faster heart rate and a whole-body reaction in which blood vessels widen. The small published studies did not report those serious events. Available clinical data are limited. This guide gives no dose or personal-use instructions.
Still unknown: Higher hormone levels do not prove less body fat, more muscle, better recovery, better sleep, more energy, or a longer life. These studies did not establish those popular claims. Long-term safety is still unclear.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
Two studies assigned healthy adults to groups by chance. Some received CJC-1295, and some received a placebo, an inactive comparison. The studies found that growth hormone and IGF-1 stayed higher for a time. Another study found changes in how growth hormone was released. These studies measured body signals, not health benefits.
Read all CJC-1295 claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- Prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults
PubMed · Journal of Clinical Endocrinology & Metabolism · Randomized trial · 2006
Source accessed
- Pulsatile GH secretion during continuous stimulation by CJC-1295
PubMed · Journal of Clinical Endocrinology & Metabolism · Human pharmacology · 2006
Source accessed
- Certain bulk drug substances that may present significant safety risks
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- CJC-1295 pharmacy compounding advisory review
U.S. Food and Drug Administration · FDA review · 2024
Source accessed
- 2026 prohibited list
World Anti-Doping Agency · Anti-doping · 2026
Source accessed